Haemonetics Back to Neutral - Analyst Blog
April 15 2013 - 10:40AM
Zacks
Haemonetics Back to
Neutral
On Apr 11, we downgraded
Haemonetics Corporation (HAE) back to our Neutral
recommendation. In spite of huge growth prospects including the
company’s recent entry in the $1.2 billion whole blood collection
market, the share price already reflects the positive events and we
do not see any catalysts to drive further upside. Moreover, we are
concerned with the uncertain economic scenario, which continues to
pose challenges for this Zacks Rank #2 (Buy) stock.
Why back to
Neutral?
Haemonetics reported a mixed third
quarter with adjusted EPS of 50 cents, surpassing both the Zacks
Consensus Estimate of 47 cents and the year-ago earnings of 43
cents. Although revenues increased 31% year over year at CER to
$247.4 million, it failed to meet the Zacks Consensus Estimate of
$252 million.
Even though margin improvement took
place during the quarter, the uncertain economic scenario continues
to pose a challenge for Haemonetics. Despite the economic
challenges, the company continued to enhance its blood management
solutions. Although the gradual recovery in the economy has
resulted in an uptrend in IMPACT sales, any hurdle in the recovery
process might hamper the growth prospects.
With the acquisition of the
transfusion medicine business of Pall Corporation for $551 million,
Haemonetics forayed into the $1.2 billion whole blood collection
market. Moreover, the company’s focus on emerging markets is
yielding results as China continues to register strong growth.
Revenue from this region is expected to accelerate over the
forthcoming period.
Other stocks worth a
look
Apart from Haemonetics, other
stocks in the MedTech sector that are currently performing well
include Given Imaging (GIVN), Medical
Action Industries Inc. (MDCI) and Cyberonics
Inc. (CYBX). All these companies carry a Zacks Rank #1
(Strong Buy).
CYBERONICS INC (CYBX): Free Stock Analysis Report
GIVEN IMAGING (GIVN): Free Stock Analysis Report
HAEMONETICS CP (HAE): Free Stock Analysis Report
MEDICAL ACTION (MDCI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Given Imaging (NASDAQ:GIVN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Given Imaging (NASDAQ:GIVN)
Historical Stock Chart
From Jul 2023 to Jul 2024